Searched for
PASCAL SORIOT
Banquets and billions: How AstraZeneca sealed a US medicine deal with TrumpAstraZeneca CEO Pascal Soriot met with U.S. President Donald Trump to finalize a medicine deal. This agreement will lower drug prices for m...- AstraZeneca to invest $50 bn in the US amid Trump tariffsAstraZeneca, a British pharmaceutical company, plans to invest $50 billion in the United States. This decision comes amid upcoming tariff i...
- AstraZeneca to invest $2.5 billion in China research and development hubAstraZeneca has announced a $2.5 billion investment in a research and development hub in Beijing, underscoring its commitment to China, its...
- AstraZeneca to buy Amolyt Pharma for $1.05 bln to boost rare-disease portfolioAstraZeneca announced its acquisition of Amolyt Pharma, a company focused on endocrine diseases, for $1.05 billion in cash. This move aims ...
- AstraZeneca targets 2024 growth but mixed views hit sharesIn almost a decade since AstraZeneca fended off a takeover by U.S. rival Pfizer, CEO Pascal Soriot has rebuilt the Anglo-Swedish drugmaker'...
- AstraZeneca on hunt for acquisitions, says CEO Pascal SoriotSoriot was tasked with turning around a troubled AstraZeneca - hit by a string of key patent losses and a spate of clinical trial failures ...
- AstraZeneca runs into 'meaningful' investor revolt over payAt an annual meeting of shareholders, 60.19% of votes were cast by shareholders in favour of approving Soriot's pay proposal, which takes h...
- We didn't overpromise on COVID-19 vaccine supplies, says AstraZeneca's CEO Pascal SoriotSoriot said the company did its best to deliver as much as it could to the EU, and while he was disappointed it could not have delivered mo...
- AstraZeneca's Pascal Soriot: Know the man behind the Covid vaccineThe development of the vaccine with scientists at Oxford University -- and their decision to make it available at cost -- has made the Angl...
- AstraZeneca expects updated COVID-19 vaccine by autumnResearchers began this work months ago when the variants were first detected, said Mene Pangalos, head of biopharmaceuticals research for A...
- AstraZeneca denounces 'me first' approach to Covid jabsAstraZeneca chief executive Pascal Soriot, speaking at a virtual event for the Davos World Economic Forum, also attacked a lack of global p...
- AstraZeneca's Covid-19 vaccine has a 'winning formula': Chief executive Pascal SoriotThe UK government announced on December 23 that the developers of the Oxford AstraZeneca vaccine had submitted their data to the Medicines ...
- AstraZeneca shares sink 8% after $39 billion Alexion buyoutChief Executive Officer Pascal Soriot had told reporters on Saturday that the deal, a bet on rare-disease and immunology drugs, was the res...
- Oxford-Astra COVID-19 vaccine shows average 70.4% efficacy in pooled studyAstraZeneca Chief Executive Officer Pascal Soriot said the drugmaker had begun submitting data to regulatory authorities around the world t...
- AstraZeneca likely to run additional global vaccine test, CEO Pascal Soriot says“Now that we’ve found what looks like a better efficacy we have to validate this, so we need to do an additional study,” CEO Pascal Soriot ...
- Post trial results, AstraZeneca CEO says smaller first dose in COVID-19 vaccine is 'big plus'The British drugmaker said on Monday its vaccine for the novel coronavirus could be around 90% effective without any serious side effects.
- AstraZeneca COVID-19 vaccine likely to protect for a year: CEOAstraZeneca said on Saturday that it had signed contracts with France, Germany, Italy and the Netherlands to supply the European Union with...
- AstraZeneca ‘On Track’ to roll out vaccine in September“We’re manufacturing indeed at risk — and that’s the only way to have the vaccine ready to go if it works,” he added. Oxford University beg...
- AstraZeneca leaves door ajar to Pfizer, despite hurdlesAstraZeneca's boss said he would engage with Pfizer if the price was right and the risks posed from forcing the British drugmaker's ops int...
- AstraZeneca to close its Bangalore R&D unitThe decision to shut the R&D centre is part of an ongoing global restructuring exercise, said the company that employs over 1,200 people in...
Load More
